Subscribe to RSS
Acute COVID-19 Infection in a Pediatric Patient with ROHHADFunding None.
The novel coronavirus (severe acute respiratory syndrome coronavirus-2) has led to a global pandemic. In the adult population, coronavirus disease 2019 (COVID-19) has been found to cause multiorgan system damage with predicted long-term sequelae. We present a case of a 10-year-old boy with a history of ROHHAD (rapid-onset obesity with hypothalamic dysregulation, hypoventilation, and autonomic dysregulation) who presented with hypoxia, emesis, and abdominal pain. Imaging found bilateral ground glass opacities in the lungs and a pericardial effusion. Laboratory evaluation was concerning for elevated inflammatory markers. Remdesivir, hydroxychloroquine, and anticoagulation (heparin and enoxaparin) were utilized. The patient's severe respiratory failure was managed with conventional mechanical ventilation, inhaled nitric oxide, and airway pressure release ventilation. We hope that this report provides insight into the course and management of the severe acute pediatric COVID-19 patient, specifically with underlying comorbidities such as ROHHAD. Clinical trial registration is none.
D.S.U. and H.K.C. conceptualized the report, drafted the initial manuscript, and assisted in revisions. M.L., M.A., S.Q., A.M., and S.A.A.-A. extracted and assembled the relevant data from the patient's hospital course, critically reviewed the manuscript for important intellectual content, and revised the manuscript. All authors contributed directly in the patient's care for an extended period of time. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Received: 17 July 2020
Accepted: 14 September 2020
Article published online:
26 October 2020
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Stuttgart · New York
- 1 Sinha IP, Harwood R, Semple MG. et al. COVID-19 infection in children. Lancet Respir Med 2020; 8 (05) 446-447
- 2 Barclay SF, Rand CM, Nguyen L. et al. ROHHAD and Prader-Willi syndrome (PWS): clinical and genetic comparison. Orphanet J Rare Dis 2018; 13 (01) 124
- 3 Ize-Ludlow D, Gray JA, Sperling MA. et al. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood. Pediatrics 2007; 120 (01) e179-e188
- 4 Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation. . Available at: rarediseases.org. Accessed May 15, 2020
- 5 Centers for Disease Control and Prevention, Provisional COVID-19 Death Counts by Sex, Age, and State. . Available at: https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Sex-Age-and-S/9bhg-hcku. Accessed May 11, 2020
- 6 Dong Y, Mo X, Hu Y. et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020; 145 (06) e20200702
- 7 Daoud EG. Airway pressure release ventilation. Ann Thorac Med 2007; 2 (04) 176-179
- 8 Guérin C, Reignier J, Richard J-C. PROSEVA Study Group. et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013; 368 (23) 2159-2168
- 9 Moghadam VD, Shafiee H, Ghorbani M, Heidarifar R. Prone positioning in management of COVID-19 hospitalized patients. Braz J Anesthesiol 2020; 70 (02) 188-190
- 10 U.S. National Library of Medicine, PROSpect: Prone and Oscillation Pediatric Clinical Trial. . Available at: https://clinicaltrials.gov/ct2/show/NCT03896763. Accessed May 11, 2020
- 11 Gautret P, Lagier J-C, Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56 (01) 105949
- 12 Chen J, Liu D, Liu L. et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19 [in Chinese]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020; 49 (02) 215-219
- 13 Wang M, Cao R, Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30 (03) 269-271
- 14 Grein J, Ohmagari N, Shin D. et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382 (24) 2327-2336